Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has received FDA approval for SKINVIVE by JUVÉDERM® to treat neck lines in adults over 21.
This marks the first hyaluronic acid injectable approved for reducing neck wrinkles and enhancing skin moisture retention.
In clinical trials, 74.8 percent of participants showed significant improvement in neck appearance after one month of treatment. SKINVIVE by JUVÉDERM® is also approved for improving cheek smoothness since 2023.
The product addresses the growing demand for solutions to ‘tech-neck,’ a condition caused by frequent device use.
Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie, stated, “The approval of SKINVIVE by JUVÉDERM® for horizontal neck wrinkles reflects Allergan Aesthetics’ commitment to developing science-driven innovations that address meaningful unmet aesthetic needs.”
